A Open-label Study to Evaluate the Safety of TRV130 in Patients With Acute Pain
Completed
Trevena Inc.
Phase 3
2015-12-01
Patients with moderate to severe pain caused by medical conditions or surgery, who require IV
opioid therapy may be enrolled in this open label safety study. Patients will be treated with
TRV130 by IV bolus, PCA (patient-controlled analgesia) administration, or both, as determined
by the investigator, for a duration not to exceed 14 days.
Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Acute Pain After Bunionectomy
Completed
Trevena Inc.
Phase 3
2016-05-01
The primary objective is to evaluate the analgesic efficacy of intravenous (IV) oliceridine
administered as needed (PRN) compared with placebo in patients with moderate to severe acute
postoperative pain after bunionectomy.
Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Acute Pain After Abdominoplasty
Completed
Trevena Inc.
Phase 3
2016-05-01
The primary objective is to evaluate the analgesic efficacy of intravenous (IV) oliceridine
administered as needed (PRN) compared with placebo in patients with moderate to severe acute
pain after abdominoplasty.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
